PDCD1 and melanoma: Gopalakrishnan et al. demonstrated that mice receiving FMT from melanoma patients who responded to anti-PD-1 immunotherapy exhibited significantly reduced tumor growth and improved treatment outcomes compared to mice receiving fecal transplants from non-responding patients [64].